Evidence map›Paper›PMID 33738381›Full record

ReviewAging medicine (Milton (N.S.W))2021

Progress in the risk assessment of hydroxychloroquine in frail elderly people.

Alberto Castagna, Giovanni Ruotolo, Ciro Manzo

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging medicine (Milton (N.S.W)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Alberto CastagnaAzienda Sanitaria Provinciale Catanzaro, Primary Care Departiment, Center for Cognitive Disorders and Dementia Catanzaro Italy.ORCID https://orcid.org/0000-0001-9136-2055
Giovanni RuotoloGeriatric Unit General Hospital Azienda Ospedaliera Pugliese-Ciaccio di Catanzaro Catanzaro Italy.
Ciro ManzoAzienda Sanitaria Locale Napoli 3 Sud Internal and Geriatric Medicine Department - Gerontorheumatological Outpatient Clinic Poliambulatorio "Mariano Lauro" - Distretto Sanitario 59 Naples Italy.ORCID https://orcid.org/0000-0002-4800-1817
ASL Roma · ITAzienda Ospedaliera Pugliese Ciaccio · ITMagna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti-inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID-19 pandemic. However, HCQ can cause QT interval prolongation. The current therapies used in COVID-19 are changing as the pandemic develops. The aim of this article is to promote a validated risk score for QT prolongation in multidimensional assessment of COVID-19 patients, especially in elderly and polypathological patients.

Indexed as

COVID‐19hydroxychloroquineQTc prolongation risk score

Identifiers

PMID33738381
PMCPMC7954841
OpenAlexW3113693791

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.